Distinct Physiologic and Inflammatory Responses Elicited in Baboons After Challenge with Shiga Toxin Type 1 or 2 from Enterohemorrhagic Escherichia Coli
Overview
Affiliations
Shiga toxin-producing Escherichia coli is a principal source of regional outbreaks of bloody diarrhea and hemolytic-uremic syndrome in the United States and worldwide. Primary bacterial virulence factors are Shiga toxin types 1 and 2 (Stx1 and Stx2), and we performed parallel analyses of the pathophysiologies elicited by the toxins in nonhuman primate models to identify shared and unique consequences of the toxemias. After a single intravenous challenge with purified Stx1 or Stx2, baboons (Papio) developed thrombocytopenia, anemia, and acute renal failure with loss of glomerular function, in a dose-dependent manner. Differences in the timing and magnitude of physiologic responses were observed between the toxins. The animals were more sensitive to Stx2, with mortality at lower doses, but Stx2-induced renal injury and mortality were delayed 2 to 3 days compared to those after Stx1 challenge. Multiplex analyses of plasma inflammatory cytokines revealed similarities (macrophage chemoattractant protein 1 [MCP-1] and tumor necrosis factor alpha [TNF-alpha]) and differences (interleukin-6 [IL-6] and granulocyte colony-stimulating factor [G-CSF]) elicited by the toxins with respect to the mediator induced and timing of the responses. Neither toxin induced detectable levels of plasma TNF-alpha. To our knowledge, this is the first time that the in vivo consequences of the toxins have been compared in a parallel and reproducible manner in nonhuman primates, and the data show similarities to patient observations. The availability of experimental nonhuman primate models for Stx toxemias provides a reproducible platform for testing antitoxin compounds and immunotherapeutics with outcome criteria that have clinical meaning.
The diverse landscape of AB5-type toxins.
Brown P, Ojiakor A, Chemello A, Fowler C Eng Microbiol. 2024; 3(4):100104.
PMID: 39628907 PMC: 11610972. DOI: 10.1016/j.engmic.2023.100104.
Intestinal tissue response to Shiga toxin exposure.
Hanson K, Weiss A mBio. 2024; 15(9):e0123224.
PMID: 39136441 PMC: 11389414. DOI: 10.1128/mbio.01232-24.
Watanabe-Takahashi M, Tamada M, Senda M, Hibino M, Shimizu E, Okuta A Commun Biol. 2021; 4(1):538.
PMID: 33972673 PMC: 8111002. DOI: 10.1038/s42003-021-02068-3.
Verotoxin Receptor-Based Pathology and Therapies.
Lingwood C Front Cell Infect Microbiol. 2020; 10:123.
PMID: 32296648 PMC: 7136409. DOI: 10.3389/fcimb.2020.00123.
Hall G, Kurosawa S, Stearns-Kurosawa D Infect Immun. 2018; 86(11).
PMID: 30150257 PMC: 6204700. DOI: 10.1128/IAI.00530-18.